IN8BIO, INC.
INAB evidence brief
What we can confirm
- BioSniper Score:
- 8.1 / 10
- Market Cap:
- $10.5M
- Lead Asset:
- inb-100 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for INAB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INAB
IN8bio (INAB) is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases, with a lead program in glioblastoma showing a median overall survival exceeding 19.5 months.
Key risk: Net loss and limited cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$10.5M
Cash Runway
—
Lead Asset
inb-100 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 1 clinical trial for IN8BIO, INC..
IN8bio (INAB) is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases, with a lead program in glioblastoma showing a median overall survival exceeding 19.5 months.
- IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases [news · 2026-05-07].
- Lead candidate INB-400 (DeltEx DRI) in newly diagnosed glioblastoma (GBM) showed a median progression-free survival of 13.0 months and median overall survival exceeding 19.5 months (not yet reached) as of June 2026 [news · 2026-06-01].
- INB-400 has Orphan Drug Designation and is in Phase 2 with 31 competitors [pipeline].
- A private placement of up to $40.2 million was announced in December 2025 to advance INB-619, a gamma-delta T cell engager, with initial proceeds extending cash runway into the first half of 2027 [news · 2025-12-19].
- As of 2026-06-30, the company reported a net loss of $4.8M and shareholders' equity of $18.4M [sec].
What works
- Lead GBM program (INB-400) demonstrated a median overall survival exceeding 19.5 months, which may represent a meaningful improvement over the standard of care that has remained unchanged for over 20 years [news · 2026-06-01].
- The company has a next-generation γδ T cell engager platform (INB-619) with initial animal data expected in 2026, supported by a $40.2 million private placement that extends cash runway into the first half of 2027 [news · 2025-12-19].
- INB-400 has Orphan Drug Designation, which may provide regulatory and commercial advantages [pipeline].
What to weigh
- The company reported a net loss of $4.8M as of 2026-06-30, indicating ongoing cash burn without approved products [sec].
- INB-400 faces a competitive landscape of 31 competitors in glioblastoma, including established therapies and other immunotherapies [pipeline].
- The preclinical T cell engager platform (INB-600) has 83 competitors, including large pharmaceutical companies such as Bristol-Myers Squibb and Genmab [pipeline].
- The company's cash runway extends only into the first half of 2027, creating near-term financing risk [news · 2025-12-19].
From the filings
Quoted directly from source documents.
Lead GBM program shows median overall survival exceeding 19.5 months
“Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).”
News · June 1, 2026
Private placement of up to $40.2 million to advance INB-619
“$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application”
News · December 19, 2025
INB-400 has Orphan Drug Designation
“Regulatory Status: Orphan Drug Designation”
Catalyst timeline
- 2023-09-08 · Phase 2 start for INB-400 (DeltEx DRI in glioblastoma) — A Phase 1b/2 study of DeltEx DRI in combination with temozolomide in recurrent or newly diagnosed glioblastoma began.
Risks & what to watch (4)›
Key risks
- Net loss and limited cash runway — Net loss of $4.8M as of 2026-06-30; cash runway only into first half of 2027 [sec] [news · 2025-12-19].
- Intense competition in GBM — INB-400 faces 31 competitors in glioblastoma, including established SOC and other immunotherapies [pipeline].
- Preclinical platform faces many rivals — INB-600 T cell engager platform has 83 competitors, including large pharma [pipeline].
- No approved products — All candidates are in Phase 1/2 or preclinical; no revenue from product sales [pipeline].
What to watch
- Presentation of updated median overall survival data for INB-400 at ASCO 2026 [news · 2026-05-07].
- Initial animal data for the γδ T cell engager platform (INB-619) expected in 2026 [news · 2026-05-07].
- R&D Day on May 21, 2026, where new clinical data and platform updates will be showcased [news · 2026-05-06].
- Cash runway and potential need for additional financing as current runway extends only into first half of 2027 [news · 2025-12-19].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run IN8BIO, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available IN8BIO, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.18 · 0% dilution
Lead: Phase 2
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
19
Total value held
$5.6M
| Holder | Shares | Value |
|---|---|---|
| alyeska investment group, l.p. | 944,319 | $1.4M |
| franklin resources inc | 914,531 | $1.4M |
| 683 capital management, llc | 724,637 | $1.1M |
| stonepine capital management, llc | 663,412 | $982K |
| bios capital management, lp | 167,805 | $248K |
| vanguard capital management llc | 88,865 | $132K |
| geode capital management, llc | 86,239 | $128K |
| vanguard fiduciary trust co | 43,570 | $65K |
| captrust financial advisors | 33,295 | $49K |
| oppenheimer & co inc | 24,033 | $36K |
Showing top 10 of 19 institutional holders of IN8BIO, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 3.4%
- Days to cover
- 3.9
- Shares short
- 296,110
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INAB short interestGovernance
Frequently asked questions
What is the AI investment thesis for IN8BIO, INC.?
IN8bio (INAB) is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases, with a lead program in glioblastoma showing a median overall survival exceeding 19.5 months.
What is IN8BIO, INC.'s lead drug candidate?
IN8BIO, INC.'s most advanced tracked candidate is inb-100 (Phase 1) for High-risk leukemias.
Who is the CEO of IN8BIO, INC.?
Mr. Tai-Wei Ho is the chief executive officer of IN8BIO, INC. (INAB).
Where is IN8BIO, INC. headquartered?
IN8BIO, INC. (INAB) is headquartered in New York, NY, United States.
What therapeutic areas does IN8BIO, INC. focus on?
IN8BIO, INC. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.